| Not Yet Recruiting | TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis NCT06733519 | Tharimmune Inc | Phase 2 |
| Not Yet Recruiting | Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy NCT07424677 | Zydus Therapeutics Inc. | Phase 3 |
| Recruiting | Biochemical Response and Clinical Outcomes in Patients With PBC NCT07449793 | RenJi Hospital | — |
| Not Yet Recruiting | Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Sarogl NCT07216235 | Zydus Therapeutics Inc. | Phase 3 |
| Not Yet Recruiting | The Value of Spleen Stiffness Measurement in Patients With PBC NCT07319169 | Universitair Ziekenhuis Brussel | N/A |
| Recruiting | A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA NCT07282353 | Cascade Pharmaceuticals, Inc | Phase 3 |
| Not Yet Recruiting | Monitoring the Response of Combination Ursodiol and Seladelpar Treatment NCT07122206 | Methodist Health System | — |
| Completed | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) NCT07049887 | Ipsen | — |
| Completed | A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury NCT06888115 | Cascade Pharmaceuticals, Inc | Phase 1 |
| Recruiting | LEOPARD Training and Validation Data Collection Study NCT06675604 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) NCT06730061 | Ipsen | Phase 3 |
| Not Yet Recruiting | LEOPARD Prospective Validation Cohort 1 NCT06723275 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Bilia NCT06447168 | Ipsen | — |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Ch NCT06525311 | Kowa Research Institute, Inc. | Phase 1 |
| Recruiting | Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis NCT06427395 | Zydus Therapeutics Inc. | Phase 3 |
| Active Not Recruiting | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ur NCT06383403 | Ipsen | Phase 3 |
| Terminated | To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate NCT06488911 | Intercept Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06417398 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Clinical Study on the Treatment of Elevated Total Bilirubin in Primary Biliary Cholangitis With Baobao Dan Cap NCT06371196 | Mei Han | Phase 4 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangi NCT06247735 | Kowa Research Institute, Inc. | Phase 2 |
| Completed | Study of [14C]CS0159 in China Healthy Subjects NCT06098027 | Cascade Pharmaceuticals, Inc | Phase 1 |
| Recruiting | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis NCT06051617 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects Wi NCT06060665 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis NCT06174402 | Han Ying | Phase 2 / Phase 3 |
| Recruiting | Detection Program for Patients With Primary Biliary Cholangitis Lost in the System NCT05919433 | Hospital Mutua de Terrassa | — |
| Recruiting | Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis NCT05751967 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Recruiting | Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis NCT05749822 | Xijing Hospital of Digestive Diseases | Phase 2 / Phase 3 |
| Completed | Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions NCT05786482 | University of Alberta | N/A |
| Completed | Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects NCT05624294 | Cascade Pharmaceuticals, Inc | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis NCT05190523 | Gannex Pharma Co., Ltd. | Phase 2 |
| Completed | Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis NCT05133336 | Zydus Therapeutics Inc. | Phase 2 / Phase 3 |
| Withdrawn | A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients NCT05293938 | Intercept Pharmaceuticals | — |
| Completed | Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC NCT05239468 | Intercept Pharmaceuticals | Phase 2 |
| Completed | A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness NCT05014672 | Calliditas Therapeutics Suisse SA | Phase 2 |
| Completed | Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Chol NCT05104853 | COUR Pharmaceutical Development Company, Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis NCT05450887 | Nanjing Chia-tai Tianqing Pharmaceutical | Phase 3 |
| Recruiting | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Ca NCT05050136 | Mirum Pharmaceuticals, Inc. | Phase 2 |
| Completed | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and NCT04950764 | Gilead Sciences | Phase 1 |
| Unknown | Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatiti NCT04376528 | West China Hospital | Phase 4 |
| Completed | Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis NCT04604652 | HighTide Biopharma Pty Ltd | Phase 2 |
| Completed | The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary C NCT06309589 | Yilihamu·Abilitifu | N/A |
| Completed | RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control NCT04620733 | Gilead Sciences | Phase 3 |
| Unknown | Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1 NCT04618575 | West China Hospital | Phase 4 |
| Completed | Combination Antiretroviral Therapy (cART) for PBC NCT03954327 | University of Alberta | Phase 2 |
| Unknown | Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II NCT04617561 | West China Hospital | Phase 4 |
| Recruiting | Clinical Research of Tapering UDCA in PBC Patients With a Complete Response NCT04650243 | Peking Union Medical College Hospital | Phase 4 |
| Terminated | Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC NCT04594694 | Intercept Pharmaceuticals | Phase 2 |
| Unknown | Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis NCT04076527 | University of Leipzig | — |
| Recruiting | National Database on Primary Biliary Cholangitis NCT05151809 | University of Milano Bicocca | — |
| Terminated | EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study NCT04265235 | University of Birmingham | N/A |
| Terminated | A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cann NCT03742973 | Eli Lilly and Company | Phase 2 |
| Terminated | Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis NCT03684187 | Yale University | N/A |
| Completed | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Int NCT03602560 | Gilead Sciences | Phase 3 |
| Unknown | A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis T NCT03703076 | SAMEY | — |
| Unknown | A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis NCT03345589 | West China Hospital | Phase 4 |
| Terminated | Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis NCT03155932 | Arena Pharmaceuticals | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary NCT03394924 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Completed | Early Identification of Myocardial Impairment in PBC NCT03545672 | RenJi Hospital | — |
| Terminated | Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholi NCT03092765 | EA Pharma Co., Ltd. | Phase 2 |
| Recruiting | Fenofibrate in Patients With Primary Biliary Cholangitis (PBC) NCT06365424 | Xijing Hospital of Digestive Diseases | Phase 2 / Phase 3 |
| Recruiting | Swiss Primary Biliary Cholangitis Cohort Study NCT03146910 | Fondazione Epatocentro Ticino | — |
| Terminated | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangit NCT02943447 | Gilead Sciences | Phase 2 |
| Unknown | The Effect of Bezafibrate on Cholestatic Itch NCT02701166 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 3 |
| Completed | The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Bili NCT03322943 | West China Hospital | — |
| Completed | A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Pat NCT02516605 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients NCT05292872 | Intercept Pharmaceuticals | — |